Skip to main content
BGI Genomics Co., Ltd. logo

BGI Genomics Co., Ltd. — Investor Relations & Filings

Ticker · 300676 ISIN · CNE100003449 Shenzhen Stock Exchange Professional, scientific and technical activities
Open in API
Filings indexed 1,656 across all filing types
Latest filing 2021-02-09 Capital/Financing Update
Country CN China
Listing Shenzhen Stock Exchange 300676

About BGI Genomics Co., Ltd.

https://www.bgi.com

BGI Genomics Co., Ltd. is a leading provider of integrated solutions for precision medicine, specializing in genomic sequencing and proteomic services. The company offers a comprehensive portfolio of clinical diagnostics and research services across various fields, including reproductive health, oncology, and infectious diseases. Key products include non-invasive prenatal testing, hereditary cancer screening, and pathogen identification tools. Leveraging proprietary DNBseq sequencing technology, BGI Genomics provides high-throughput, cost-effective genomic data analysis to healthcare providers, research institutions, and pharmaceutical companies worldwide. The organization focuses on advancing personalized medicine through large-scale genomic research and the development of innovative diagnostic applications, aiming to improve health outcomes by making advanced genetic insights accessible to a global population.

Recent filings

Filing Released Lang Actions
关于开展外汇衍生品交易业务的可行性分析报告
Capital/Financing Update Classification · 95% confidence The document is a detailed feasibility analysis report regarding the company's plan to engage in foreign exchange derivative trading. It discusses the background, necessity, types of transactions, risk analysis, and risk control measures related to this business activity. There is no indication that this is an announcement of a report publication or a brief summary. The content is focused on a specific business activity and its risk management rather than financial results, governance changes, or regulatory filings. It does not fit categories like Annual Report, Interim Report, or Earnings Release. It is a specialized report analyzing a financial activity (foreign exchange derivatives trading) feasibility and risk, which aligns best with a Capital/Financing Update (CAP) as it relates to the company's financing and risk management strategy involving derivatives. The document length is under 5,000 characters but contains substantive content, so it is not a mere announcement. Therefore, the most appropriate classification is CAP with high confidence.
2021-02-09 Chinese
第二届监事会第二十七次会议决议公告
Regulatory Filings Classification · 95% confidence The document is a formal announcement of resolutions passed at the 27th meeting of the second Supervisory Board of Shenzhen BGI Genomics Co., Ltd. It details the meeting procedures, voting results, and specific agenda items such as related party transactions, donations, use of raised funds, foreign exchange derivative transactions, and cash management. The document is an official disclosure of meeting decisions and does not contain financial statements or detailed financial analysis. It is not an annual or interim report, earnings release, or audit report. It is also not a proxy solicitation or voting results declaration. The document is a regulatory announcement of board-level decisions, specifically from the Supervisory Board, which fits best under the category of Regulatory Filings (RNS) as it does not fit more specific categories like Board/Management Information (MANG) which typically covers changes in board or management personnel. The document length is about 3,077 characters, which is relatively short and consistent with an announcement rather than a full report.
2021-02-09 Chinese
第二届董事会第二十九次会议决议公告
Board/Management Information Classification · 95% confidence The document is a detailed announcement of resolutions passed at the 29th meeting of the second board of directors of Shenzhen BGI Genomics Co., Ltd. It includes information about board meeting procedures, voting results, and approvals of various corporate matters such as related party transactions, donations, use of raised funds, credit facilities, foreign exchange derivative transactions, cash management, capital changes, and scheduling of a shareholders meeting. The document is not a financial report, earnings release, or audit report. It is not a proxy solicitation or voting results announcement but rather a formal disclosure of board decisions and management-level approvals. This fits the category of Board/Management Information (MANG), which covers announcements of changes or decisions by the board or senior management. The document length and content confirm it is not a brief announcement or a report publication notice. Therefore, the classification is MANG with high confidence.
2021-02-09 Chinese
中信证券股份有限公司关于公司开展外汇衍生品交易业务的核查意见
Regulatory Filings Classification · 95% confidence The document is a detailed opinion and verification report from CITIC Securities regarding Shenzhen BGI Genomics Co., Ltd.'s plan to conduct foreign exchange derivative trading business. It includes descriptions of the business purpose, types of transactions, risk analysis, risk control measures, accounting policies, and the impact on the company. It also contains the review and approval opinions from the board of directors, independent directors, supervisory board, and the sponsoring institution. The document is not a financial report like an annual or interim report, nor is it a brief announcement or voting result. It is a formal verification opinion related to a specific business activity, which aligns with the category of Regulatory Filings (RNS) as it does not fit into other more specific categories such as capital updates or management changes. The document length is under 5,000 characters, but it contains substantive content rather than just an announcement of a report publication, so it is not an RPA. Therefore, the best classification is Regulatory Filings (RNS).
2021-02-09 Chinese
关于召开2021年第一次临时股东大会的通知
AGM Information Classification · 95% confidence The document is a detailed notice about convening the 2021 first extraordinary general meeting (临时股东大会) of Shenzhen BGI Genomics Co., Ltd. It includes information about the meeting date, agenda items for shareholder voting, voting procedures (including online voting), registration details, and proxy authorization forms. The content is focused on informing shareholders about the meeting logistics and agenda, not the results of the meeting or any financial report. There is no indication that this is a voting results announcement or a proxy solicitation document. It is a formal meeting notice, which fits the category of AGM Information (AGM-R). The document length (5750 characters) and detailed meeting information support this classification rather than a brief announcement or a report publication notice.
2021-02-09 Chinese
关于使用募集资金向子公司增资及提供借款以实施募投项目的公告
Capital/Financing Update Classification · 95% confidence The document is a detailed announcement from Shenzhen BGI Genomics Co., Ltd. regarding the use of raised funds to increase capital and provide loans to subsidiaries for implementing investment projects. It includes specifics about the amounts, the subsidiaries involved, financial data of these subsidiaries, and the approval process including board and supervisory committee resolutions, independent directors' opinions, and the sponsor's verification. The document references regulatory compliance with Shenzhen Stock Exchange rules and the China Securities Regulatory Commission approval. It is not a full annual or interim financial report, nor an earnings release or audit report. It is a formal announcement about capital use related to fundraising and financing activities, specifically the use of proceeds from a private placement to subsidiaries. This fits the definition of a Capital/Financing Update (CAP). The document length and detail confirm it is not a brief announcement or a report publication notice, but a substantive update on capital use and financing.
2021-02-09 Chinese

Browse filings by year

10 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.